The Global Pandemic Accord: Forging a New Shield for Global Health Security

The devastating COVID-19 pandemic, which brought the world to a standstill, served as a catastrophic stress test for global health governance, revealing deep fissures in our collective ability to prevent, prepare for, and respond to infectious disease threats. In its wake, the international community, under the aegis of the World Health Organization (WHO), embarked on an ambitious and historically significant endeavor: the negotiation of a legally binding Global Pandemic Accord. This treaty represents a once-in-a-generation opportunity to rectify the systemic failures of the past and build a more resilient and equitable architecture for global health security.

The negotiations, conducted by an Intergovernmental Negotiating Body (INB) established in December 2021, have been a complex and often fraught process of global diplomacy. The goal is to create a framework that transcends the limitations of existing instruments, primarily the International Health Regulations (IHR 2005). While the IHR provides a legal framework for countries to work together in response to public health emergencies, the pandemic exposed its inadequacies, including a lack of enforcement mechanisms and a failure to ensure equitable access to life-saving tools.

This new accord is being negotiated under Article 19 of the WHO Constitution, a powerful provision that allows the World Health Assembly (WHA)—the WHO’s main governing body—to adopt conventions or agreements on any matter within the WHO’s competence. The use of Article 19 is rare; the only other treaty adopted under this provision is the 2003 WHO Framework Convention on Tobacco Control. This choice signals the international community’s intent to create an instrument with significant legal weight, binding upon the nations that ratify it.

The Core Pillars: A New Paradigm for Preparedness

The draft accord is built on a foundation of collective solidarity and equity, aiming to ensure that the entire world is better protected from future pandemics. Its objectives are multifaceted, addressing the full cycle of pandemic risk from prevention to long-term recovery. The central pillars of the proposed agreement can be understood as a comprehensive strategy for global resilience.

1. Prevention and Surveillance through a ‘One Health’ Approach: A cornerstone of the accord is the institutionalization of the ‘One Health’ principle. This integrated, unifying approach recognizes that the health of humans, domestic and wild animals, plants, and the wider environment are inextricably linked. Approximately 75% of emerging infectious diseases are zoonotic, meaning they originate in animals. The accord seeks to strengthen global surveillance at the human-animal-environment interface, promoting coordinated monitoring to detect novel pathogens with pandemic potential before they spill over into human populations. This involves enhancing veterinary services, monitoring wildlife health, and addressing environmental drivers of disease emergence like deforestation and climate change.

2. Strengthening Pandemic Preparedness and Health System Resilience: The accord calls for signatory nations to significantly invest in their core public health capacities. This includes building a skilled health workforce, strengthening primary healthcare systems, and ensuring robust laboratory and diagnostic capabilities. The aim is to create resilient health systems that can withstand the shock of a pandemic, maintain essential health services, and rapidly scale up response measures without collapsing.

3. Equitable Access to Pandemic Countermeasures: Perhaps the most critical and contentious pillar is the commitment to ensuring timely, equitable, and unhindered access to pandemic countermeasures, including vaccines, diagnostics, therapeutics, and personal protective equipment (PPE). The “vaccine apartheid” that characterized the COVID-19 response, where wealthy nations hoarded supplies while lower-income countries were left waiting, is a central failure the accord seeks to prevent from ever happening again.

Fun Fact: The 1918 influenza pandemic, often called the “Spanish Flu,” infected an estimated 500 million people—about one-third of the world’s population at the time—and caused 50 to 100 million deaths, far exceeding the death toll of World War I. It serves as a stark historical reminder of the devastating potential of pandemics.

The Sticking Point: The Pathogen Access and Benefit-Sharing (PABS) System

The heart of the debate on equity lies within the proposed Pathogen Access and Benefit-Sharing (PABS) System. This mechanism is designed to create a new global compact based on mutual trust and tangible benefits.

• Access: The “access” component requires countries to rapidly and reliably share samples of newly detected pathogens and their genetic sequence data with a global network of laboratories coordinated by the WHO. This immediate sharing is crucial for the rapid scientific assessment of the threat and the swift development of diagnostic tests, vaccines, and treatments.

• Benefit-Sharing: In return for this access, the “benefit-sharing” component would legally bind manufacturers of pandemic countermeasures to share the fruits of their research. The draft text has proposed a model where pharmaceutical companies would contribute a percentage of their products in real-time during a pandemic. For instance, a leading proposal suggests that 10% of production be donated to the WHO for distribution to the most vulnerable populations, and another 10% be made available at affordable, not-for-profit prices to low- and middle-income countries.

This quid pro quo has become the central battleground of the negotiations. Developing countries, particularly the Africa Group and the “Group for Equity,” have insisted on strong, legally binding benefit-sharing commitments. They argue that without such guarantees, the system would perpetuate the colonial-era dynamic of resource extraction, where pathogens (a biological resource) are taken from the Global South, commercialized in the Global North, and the resulting life-saving products are sold back at prices they cannot afford.

Conversely, developed countries with strong pharmaceutical sectors and some industry groups have pushed back, expressing concerns that mandatory benefit-sharing could stifle innovation. They argue that the high financial risks of research and development require the protection of intellectual property (IP) rights and market-based incentives. Finding a compromise that guarantees both rapid pathogen sharing and concrete, enforceable benefit-sharing has been the single greatest challenge, leading to a major deadlock in the negotiations.

The 2024-2025 Negotiations: Deadlock, Extension, and the Path Forward

The initial deadline for finalizing the Pandemic Accord was the 77th World Health Assembly in May 2024. However, despite intense, round-the-clock negotiations, the INB could not reach a consensus on a final text. The deep divisions, primarily over the PABS system, intellectual property waivers during pandemics, and the creation of a sustainable financing mechanism, proved too wide to bridge in time.

Recognizing the catastrophic implications of complete failure, the WHA made a critical decision in June 2024: it extended the mandate of the Intergovernmental Negotiating Body. Member states agreed to continue negotiations with the goal of finalizing the accord by the World Health Assembly in 2025. This extension was a pragmatic acknowledgment of the treaty’s complexity and political sensitivity. It provided much-needed breathing room for negotiators to return to their capitals, refine their positions, and seek creative compromises.

Simultaneously, the WHA successfully adopted a targeted package of amendments to the International Health Regulations (IHR 2005). These amendments, which were negotiated on a parallel track, introduced the concept of a “pandemic emergency” as a higher level of alert, strengthened provisions for national IHR focal points, and created mechanisms for solidarity-based financing. The successful adoption of these IHR amendments provided a much-needed political victory and a positive momentum, demonstrating that multilateral health diplomacy, while difficult, is not dead.

Mnemonic for Core Accord Principles: To remember the key action areas of the Pandemic Accord, use the mnemonic “PREPARE”:

• Pathogen Access & Benefit-Sharing
• Resilient Health Systems
• Equitable Access to Countermeasures
• Prevention via ‘One Health’
• Accountability & Global Coordination
• Research & Development Ecosystem
• Enhanced Financing

Comparing the IHR (2005) and the Proposed Pandemic Accord

To understand the new treaty’s value, it’s essential to see how it complements the existing IHR.

Critical Policy Appraisal

Fun Fact: The global economic cost of the COVID-19 pandemic is estimated to be over $15 trillion. The annual investment needed to strengthen global pandemic preparedness is estimated at around $31 billion—a fraction of the cost of failure. This makes preparedness one of the highest-return investments in public policy.

India’s Crucial Role in the Negotiations

India’s position in the Pandemic Accord negotiations is uniquely complex and influential. As the “pharmacy of the world,” it is a global leader in vaccine and drug manufacturing. At the same time, as a leading voice for the Global South, it has a deep-seated commitment to equity and justice in global health. This duality shapes its negotiating stance.

India has been a strong advocate for a legally binding mechanism for equitable access. It has championed proposals that would ensure technology transfer and the diversification of manufacturing, particularly to developing countries, to prevent the supply chain bottlenecks seen during COVID-19. Along with South Africa, India was at the forefront of the push for a TRIPS waiver at the World Trade Organization (WTO), and it has carried this spirit into the Pandemic Accord negotiations, arguing that IP rules must not stand in the way of saving lives during a global health crisis.

Simultaneously, India’s burgeoning pharmaceutical industry has interests to protect. Therefore, its negotiators must walk a fine line, balancing the call for global equity with the need to maintain a favorable environment for its domestic innovators and manufacturers. India’s ability to help broker a compromise that is acceptable to both developed and developing nations will be a critical factor in the ultimate success or failure of the accord.

Analytical Lens: UPSC Focus (Mains & Prelims)

Conceptual Basis: The legal foundation for the Pandemic Accord is Article 19 of the WHO Constitution, which grants the World Health Assembly the power to adopt legally binding conventions. The accord is designed to operate in conjunction with the International Health Regulations (IHR 2005), strengthening and supplementing the existing legal framework for global health security.

UPSC Integration: Connecting the Dots:

• GS Paper 2 (International Relations & Governance): The Pandemic Accord is a prime case study in multilateral negotiations, the functioning of international organizations (WHO), and the persistent North-South divide. It touches upon themes of global governance, state sovereignty, and the challenges of creating binding international law.
• GS Paper 3 (Science & Technology, Economy): The debate over the PABS system and Intellectual Property Rights (IPR) is directly linked to the TRIPS Agreement of the WTO. The topic also involves biotechnology, vaccine development (R&D), global supply chain management, and the economic impact of pandemics.
• GS Paper 4 (Ethics, Integrity, and Aptitude): The core of the accord revolves around ethical principles of equity, justice, and fairness. It raises questions about the moral obligations of nations and corporations during a global crisis and the inherent value of human life versus commercial interests.

Future Impact and Policy Relevance: The outcome of these negotiations will have profound long-term consequences. A successful and robust accord could usher in a new era of global cooperation, making the world significantly safer from the next pandemic threat. It could foster a more equitable distribution of health technologies and strengthen health systems globally. Conversely, a failure to agree on a meaningful treaty would signal a retreat from multilateralism, leaving the world dangerously vulnerable. It would likely lead to a fragmented response in the next crisis, characterized by the same nationalism, competition, and inequity that plagued the COVID-19 response, but likely with even more devastating results. For India, the accord is a critical arena to cement its role as a global leader, bridging divides and shaping the future of global health governance.

Practice Question (Prelims): Which of the following statements most accurately describes the legal basis and primary objective of the Pathogen Access and Benefit-Sharing (PABS) system proposed in the Global Pandemic Accord?

a) It is a voluntary mechanism under the IHR (2005) that encourages countries to share pathogen data for research purposes. b) It is a legally binding system under Article 21 of the WHO Constitution that focuses exclusively on financial compensation for pathogen samples. c) It is a legally binding system proposed under the new Pandemic Accord (Article 19) that links mandatory pathogen sharing with legally enforceable equitable access to the resulting countermeasures. d) It is a framework managed by the World Bank to fund vaccine research in developing countries.

Answer and Explanation: c) It is a legally binding system proposed under the new Pandemic Accord (Article 19) that links mandatory pathogen sharing with legally enforceable equitable access to the resulting countermeasures. Explanation: The PABS system is the central equity mechanism of the new Pandemic Accord, which is being negotiated under Article 19 of the WHO Constitution. Its core principle is the quid pro quo of “access” (pathogen sharing) and “benefit-sharing” (equitable access to vaccines, etc.). It is intended to be legally binding, unlike the weaker, non-binding recommendations in the IHR.

Practice Question (Mains): (15 Marks) “The negotiations for the Global Pandemic Accord represent a fundamental conflict between national interest and global solidarity.” Critically analyze this statement, highlighting the major points of contention, and discuss the role India can play in bridging the divide to forge a meaningful and effective treaty.

Mind Map Outline (Revision Structure)

• Global Pandemic Accord
  • Genesis & Rationale
    • Failures during COVID-19 Pandemic
    • Inadequacies of International Health Regulations (IHR 2005)
    • Decision by the World Health Assembly (WHA)
  • Legal Foundation
    • Article 19, WHO Constitution
      • Power to adopt binding conventions
      • Comparison with Framework Convention on Tobacco Control (FCTC)
    • Relationship with IHR (2005) - Complementary, not replacement
  • Core Pillars & Objectives (Mnemonic: PREPARE)
    • Pathogen Access & Benefit-Sharing (PABS)
      • Access Component: Rapid data/sample sharing
      • Benefit-Sharing Component: Equitable access to countermeasures (vaccines, diagnostics)
    • Resilient Health Systems
      • Strengthening workforce, primary care, labs
    • Equitable Access to Countermeasures
      • Addressing “vaccine apartheid”
      • Global supply chain and logistics networks
    • Prevention via ‘One Health’
      • Integrating human, animal, and environmental health
      • Focus on zoonotic disease surveillance
    • Accountability & Global Coordination
      • Proposed Conference of the Parties (COP)
    • Research & Development Ecosystem
      • Accelerating R&D and diversifying manufacturing
    • Enhanced Financing
      • Proposals for a dedicated pandemic fund
  • Major Negotiation Challenges & Sticking Points
    • The PABS System Deadlock
      • Developing Countries’ Stance: Legally binding benefit-sharing
      • Developed Countries’ Stance: Concerns over innovation and IP
    • Intellectual Property (IP) Rights
      • Debate on IP waivers during pandemics (link to TRIPS)
    • Financing Mechanism
      • Voluntary vs. Assessed Contributions
    • Sovereignty vs. Global Solidarity
      • The central tension of the negotiations
  • Negotiation Timeline & Recent Developments (2024-2025)
    • Failure to meet May 2024 deadline
    • Extension of INB mandate to 2025
    • Successful adoption of IHR (2005) amendments in parallel
  • India’s Role
    • Dual position: “Pharmacy of the World” and “Voice of the Global South”
    • Advocacy for equity, technology transfer
    • Balancing domestic industry interests
    • Potential role as a bridge-builder
  • UPSC Relevance
    • GS-2: Multilateralism, WHO, Global Governance
    • GS-3: IPR, TRIPS, S&T, Economic Impacts
    • GS-4: Ethics of Equity and Global Justice